索拉非尼联合TACE对晚期肝癌患者肝功能及血清VEGF的影响

目的：探讨索拉非尼联合经皮肝动脉化疗栓塞术（TACE）对晚期肝癌患者肝功能及血清血管内皮生长因子（VEGF）的影响。方法：我院2013年12月～2014年12月收治68例晚期肝癌患者，按随机数字表法分为对照组（34例）与观察组（34例）。对照组行TACE治疗，观察组同时使用索拉非尼治疗。检测两组治疗前后丙氨酸氨基转移酶（ALT）、白蛋白（ALB）、总胆红素（TBIL）等肝功能指标和血清VEGF水平。结果：两组治疗后ALT、TBIL水平显著升高（P<0.05），观察组ALT、TBIL水平（56.3±5.8）U/L和（17.6±2.5） g/L显著低于对照组（P<0.05）；较对照组，观察组血清VEGP水平（105.4±22.6）μg/mL低，差异有统计学意义（P<0.05）。结论：索拉非尼联合TACE治疗晚期肝癌能有效保护肝功能，抑制血清VEGF水平升高。

Effect of sorafenib combined with TACE on liver function and serum VEGF in patients with advanced liver cancer

Objective:To investigate the effect of sorafenib combined with transcatheter arterial chemoembolization (TACE) on liver function and serum vascular endothelial growth factor (VEGF) in patients with advanced liver cancer. Methods:68 patients with advanced liver cancer treated in our hospital from December 2013 to December 2014 were taken as the research objects and were divided into the control group (34 cases) and the observation group (34 cases) according to the random number table method. The control group were treated with TACE while the observation group were treated with sorafenib at the same time. Liver function indexes such as alanine aminotransferase (ALT), albumin (ALB) and total bilirubin (TBIL) and serum VEGF levels in the two groups were detected before and after the treatment. Results:The levels of ALT and TBIL in the two groups after the treatment increased significantly (P<0.05) and those in the observation group [(56.3 ±5.8)U/L,(17.6 ±2.5)g/L] were significantly lower than those in the control group (P<0.05);Compared with the control group, the serum VEGP level of the observation group [(105.4±22.6)μg/mL ] was lower(P<0.05). Conclusion:Sorafenib combined with TACE in the treatment of advanced liver cancer can effectively protect liver function and inhibit the increase of serum VEGF levels.